- Home
- RPRX vs COHR Comparison
RPRX vs COHR Comparison
Compare RPRX & COHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- COHR
- Stock Information
- Founded
- RPRX 1996
- COHR 1971
- Country
- RPRX United States
- COHR United States
- Employees
- RPRX N/A
- COHR N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- COHR Electronic Components
- Sector
- RPRX Health Care
- COHR Technology
- Exchange
- RPRX Nasdaq
- COHR Nasdaq
- Market Cap
- RPRX 15.6B
- COHR 14.5B
- IPO Year
- RPRX 2020
- COHR 1987
- Fundamental
- Price
- RPRX $35.87
- COHR $90.83
- Analyst Decision
- RPRX Strong Buy
- COHR Strong Buy
- Analyst Count
- RPRX 3
- COHR 16
- Target Price
- RPRX $45.33
- COHR $109.40
- AVG Volume (30 Days)
- RPRX 3.1M
- COHR 5.6M
- Earning Date
- RPRX 08-06-2025
- COHR 08-13-2025
- Dividend Yield
- RPRX 2.45%
- COHR N/A
- EPS Growth
- RPRX 54.86
- COHR N/A
- EPS
- RPRX 2.32
- COHR N/A
- Revenue
- RPRX $2,305,243,000.00
- COHR $5,810,115,000.00
- Revenue This Year
- RPRX $33.77
- COHR $10.57
- Revenue Next Year
- RPRX $4.62
- COHR $7.08
- P/E Ratio
- RPRX $15.45
- COHR N/A
- Revenue Growth
- RPRX 3.02
- COHR 23.42
- 52 Week Low
- RPRX $24.05
- COHR $45.58
- 52 Week High
- RPRX $38.00
- COHR $123.25
- Technical
- Relative Strength Index (RSI)
- RPRX 42.45
- COHR 45.60
- Support Level
- RPRX $35.48
- COHR $90.27
- Resistance Level
- RPRX $36.99
- COHR $95.97
- Average True Range (ATR)
- RPRX 0.68
- COHR 4.03
- MACD
- RPRX -0.14
- COHR -0.89
- Stochastic Oscillator
- RPRX 7.28
- COHR 21.95
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About COHR Coherent Corp.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.